Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen's Repatha Meets Endpoints In GAUSS-3 Trial

This article was originally published in Scrip

Executive Summary

Results from Amgen's Phase III GAUSS-3 trial evaluating Repatha (evolocumab) in patients with high cholesterol have added to the growing evidence that the novel drug has the ability to reduce LDL (low-density lipoprotein) cholesterol in those patients who cannot tolerate statins or decrease levels of this 'bad' cholesterol through diet.